BioStock: Iconovo on the way to profitability

Iconovo, a leading developer of inhalation products, consolidates its financial targets for 2027 – revenues of 250 MSEK with an EBIDTA margin of 50 percent. Approximately 85 percent of the revenue is expected to come from projects that have already been initiated. In addition, the company expects to achieve profitability during one quarter as early as next year and 2025, as well as full-year profitability in 2026. BioStock contacted CEO Johan Wäborg to gain a deeper understanding of the company’s goals.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/08/iconovo-on-the-way-to-profitability/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se